ImmunityBio, Inc. (IBRX) Stock: Slides 7.25% Despite Major Breakthrough in Bladder Cancer Treatment

TLDR ImmunityBio stock tumbles 7.25% to $9.27 despite promising ANKTIVA trial data. ANKTIVA delivers a 71% complete response rate in a 100-patient bladder cancer trial. Bladder cancer responses last a median 26.6 months, with some beyond 53 months. Three-year data show 84% cystectomy-free survival among responding patients. FDA expands ANKTIVA use as trial reports no [...]

The post ImmunityBio, Inc. (IBRX) Stock: Slides 7.25% Despite Major Breakthrough in Bladder Cancer Treatment appeared first on Blockonomi.